Acrotech Biopharma

Focus: Acrotech Biopharma is a public specialty pharmaceutical company headquartered in New Jersey focused on oncology and hematology therapeutics. The company operates a portfolio of approved specialty drugs with several pipeline programs in active development.

Neurology

Profile data last refreshed 1h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Acrotech Biopharma

AI assessmentNot Hiring

No open roles listed right now. Follow Acrotech Biopharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

5/9 — Partial

Company HealthStrong

Pipeline

Late-stage

3 Phase 3+

LOE Risk

1 imminent

BELEODAQ

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

EVOMELA

Multiple myeloma

Peak7.4yr

Anchor product in peak lifecycle stage with patent protection extending to 2034; core revenue driver for the specialty franchise.

Help build intelligence for Acrotech Biopharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Portfolio spans multiple oncology franchises (peripheral T-cell lymphoma, multiple myeloma, acute lymphoblastic leukemia) with 3 Phase 3 programs providing near-term clinical readouts
Peak revenue products (EVOMELA, MARQIBO KIT, KHAPZORY) provide stable cash generation while pipeline diversification reduces single-asset risk
Recent acquisition by Spectrum Pharmaceuticals (June 2026) signals potential for expanded resources and enhanced commercial infrastructure

Watch Out For

Patent cliff exposure with 5 of 8 marketed products approaching or entering LOE between 2027-2034, requiring aggressive pipeline advancement to offset revenue decline
Zero active job openings despite public status suggests flat or declining headcount; limited visible hiring may signal consolidation phase post-acquisition

Generated by Claude from Acrotech Biopharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

FUSILEV

Supportive care / hematologic malignancies

LOE Approaching

Facing loss of exclusivity approaching; likely requires combination strategy with other products to maintain market position.

BELEODAQ

Peripheral T-cell lymphoma

LOE Approaching1.2yr

Histone deacetylase inhibitor with imminent LOE in October 2027; Phase 3 expansion programs ongoing but erosion expected within 18 months.

MARQIBO KIT

Acute lymphoblastic leukemia

Peak

Liposomal formulation in peak lifecycle; early-stage Phase 1 sarcoma expansion indicates label extension strategy to extend commercial life.

ALKERAN

Multiple myeloma / stem cell transplant conditioning

LOE Approaching

Alkylating agent facing LOE with no specified exclusivity date; paired with EVOMELA in the melphalan franchise, suggests portfolio consolidation risk.

KHAPZORY

Supportive care / chemotherapy adjunct

Peak12.6yr

Longest patent extension (2039); supportive care cornerstone with stable demand and late-stage LOE provides revenue cushion.

FOLOTYN

Peripheral T-cell lymphoma

LOE Approaching

Folate analog inhibitor with active Phase 3 expansion into non-Hodgkin's lymphoma and relapsed PTCL; LOE timeline not specified but approaching cliff.

ADQUEY

Atopic dermatitis

Launch10.3yr

Recently launched oncology-adjacent asset with Phase 3 dermatology indication; represents portfolio diversification and longest-dated LOE protection (2036).

Pipeline & Clinical Trials

Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry

Peripheral T-cell Lymphoma

N/A

Clinical Trials (1)

NCT01110733Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry

N/A

peripheral T-cell lymphoma registry

Peripheral T-cell Lymphoma

N/A

Marqibo

Sarcoma

Phase 1

Clinical Trials (3)

NCT04448834Blincyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphi CD19+ ALL

Phase 2

NCT04243434PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients

Phase 1

Fusilev

Non Hodgkin's Lymphoma

Phase 1

Clinical Trials (1)

NCT01789723Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn

Phase 1

Folotyn

Non-Small Cell Lung Cancer

Phase 1

Clinical Trials (2)

NCT01820091Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn®

Phase 1

NCT02594267A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)

vincristine sulfate liposome

Acute Lymphoblastic Leukemia

Phase 1/2

Clinical Trials (3)

NCT00144963Liposomal Vincristine Plus Dexamethasone in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Phase 1/2

NCT01851551Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL

Folotyn and Leucovorin

Relapsed Peripheral T-Cell Lymphoma

Phase 2

Clinical Trials (1)

NCT02106650Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological Malignancies

Phase 2

blinatumomab

B-cell Acute Lymphoblastic Leukemia

Phase 2

melphalan

Multiple Myeloma

Phase 2

Clinical Trials (2)

NCT00925782PK Study of Melphalan HCL & Alkeran for Injection of MA Conditioning in MM Patients of Autologous Transplantation

Phase 2

NCT01660633Safety & Efficacy Study High Dose Evomela Injection for MA Conditioning in MM Patients With Autologous Transplantation

pralatrexate

Peripheral T-cell Lymphoma

Phase 3

Clinical Trials (5)

NCT01118624Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer

Phase 2

NCT00722553Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder

difamilast

Atopic Dermatitis

Phase 3

Clinical Trials (2)

NCT05608343This Study is to Assess the Efficacy of Difamilast Ointment in Mild to Moderate Atopic Dermatitis(AD)

Phase 3

NCT05571943A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic Dermatitis

belinostat

Peripheral T-cell Lymphoma

Phase 3

Clinical Trials (5)

NCT06072131To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

Phase 3

NCT05170334Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 8 approved products, 30 clinical trials

Top TAs: Oncology, Immunology, Infectious Diseases

Publications: 4 in PubMed

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Portfolio Health

Launch1 (13%)

Peak3 (38%)

LOE Approaching4 (50%)

8 total products

Therapeutic Area Focus

Oncology

7 marketed27 pipeline

Immunology

2 marketed2 pipeline

Infectious Diseases

1 marketed

Neurology

1 marketed

Marketed

Pipeline

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Research Publications(4)

Recent peer-reviewed publications with author affiliations at this company

Pralatrexate injection combined with oral leucovorin for mucositis management in PTCL/CTCL treatment: a multicenter phase 2 trial.

Blood neoplasia

2025

PMID:40546726

Comparative Safety, Bioavailability, and Pharmacokinetics of Oral Dexamethasone, 4-mg and 20-mg Tablets, in Healthy Volunteers Under Fasting and Fed Conditions: A Randomized Open-label, 3-way Crossover Study.

NCT01222780To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer

Phase 1

NCT00145041Pharmacokinetic Study of Liposomal Vincristine in Patients With Malignant Melanoma & Hepatic Dysfunction

Phase 1

NCT00364923Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Phase 2

NCT02680795Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes

Phase 1

Clinical lymphoma, myeloma & leukemia

2020

PMID:32900662

Acrotech Biopharma

About Acrotech Biopharma

Why Work Here

Key Products

Watch Out For

Products & Portfolio (4)

Pipeline & Clinical Trials

Recent News · Acrotech Biopharma(1)

Open Jobs (0)

Hiring Trend

Research Publications(4)